Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model
- Equal contributors
1 Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, China
2 Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China
BMC Cancer 2012, 12:166 doi:10.1186/1471-2407-12-166Published: 4 May 2012
Additional file 1:
Table S1. RT-PCR primer sequences and reaction conditions.
Format: DOC Size: 45KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional file 2:
Figure S1. Combined treatment with rapamycin and bortezomib inhibits SMMC7721 proliferation. (A) Proliferation of SMMC7721 cells was evaluated by using Cell Counting Kit-8 (CCK-8) at indicated time points. (B) SMMC7721 cells were treated with rapamycin (10 ng/ml), bortezomib (100 nM) or both agents. Cell cycle analysis was carried out after 24 h. One representative experiment of three is shown.
Format: TIFF Size: 463KB Download file
Additional file 3:
Figure S2. Rapamycin plus bortezomib causes enhanced apoptosis. (A) SMMC7721 cells were treated with rapamycin (10 ng/ml), bortezomib (100 nM) or the combination for 24 or 48 h and stained with Hoechst 33342 (magnification, ×400). (B, C) The quantification of apoptotic cells induced by rapamycin and bortezomib was further confirmed by flow cytometry analysis. *P < 0.01, versus control group; **P < 0.001, versus control group; #P < 0.05, versus bortezomib treatment group at 48 h.
Format: TIFF Size: 1.1MB Download file
Additional file 4:
Figure S3. Bortezomib significantly suppressed rapamycin mediated Akt phosphorylation in SMMC7721 cells. (A, B) SMMC7721 cells were cultured in control media, rapamycin (10 ng/ml), bortezomib (100 nmol/L), or rapamycin and bortezomib for 24 h. *P < 0.05, versus control group; **P < 0.01, versus control group; #P < 0.01, versus rapamycin treatment group.
Format: TIFF Size: 66KB Download file